Fraile R J, Samson M K, Buroker T R, O'Bryan R, Baker L H, Vaitkevicius V K
Cancer Treat Rep. 1978 Oct;62(10):1599-601.
Sixteen patients with disseminated squamous cell carcinoma of the lung and 26 patients with adenocarcinoma of the colon and rectum were given rubidazone. Only one partial remission was observed in a previously untreated patient who had local recurrence of a rectal adenocarcinoma. The main toxic effects observed in previously treated patients consisted of leukopenia and thrombocytopenia. Also observed were anorexia, nausea, vomiting, alopecia, fever, and chills. Cardiotoxicity was observed in one patient after a total dose of 720 mg/m2 of rubidazone. It is concluded that rubidazone is a relatively inactive compound in the management of these two diseases.
16例肺播散性鳞状细胞癌患者和26例结肠直肠癌患者接受了鲁比达唑治疗。在1例先前未接受过治疗、直肠腺癌局部复发的患者中仅观察到1例部分缓解。在先前接受过治疗的患者中观察到的主要毒性作用包括白细胞减少和血小板减少。还观察到厌食、恶心、呕吐、脱发、发热和寒战。1例患者在接受了总量为720mg/m²的鲁比达唑治疗后出现了心脏毒性。得出的结论是，鲁比达唑在治疗这两种疾病方面是一种相对无活性的化合物。
